ES2432082T3 - Uso de la variante de corte y empalme MGF del factor de crecimiento I similar a la insulina para la prevención del daño miocárdico - Google Patents

Uso de la variante de corte y empalme MGF del factor de crecimiento I similar a la insulina para la prevención del daño miocárdico Download PDF

Info

Publication number
ES2432082T3
ES2432082T3 ES03737378T ES03737378T ES2432082T3 ES 2432082 T3 ES2432082 T3 ES 2432082T3 ES 03737378 T ES03737378 T ES 03737378T ES 03737378 T ES03737378 T ES 03737378T ES 2432082 T3 ES2432082 T3 ES 2432082T3
Authority
ES
Spain
Prior art keywords
polypeptide
mgf
polynucleotide
fgm
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03737378T
Other languages
English (en)
Spanish (es)
Inventor
Geoffrey Goldspink
Paul Goldspink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College London
University of Illinois at Urbana Champaign
University of Illinois System
Original Assignee
University College London
University of Illinois at Urbana Champaign
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College London, University of Illinois at Urbana Champaign, University of Illinois System filed Critical University College London
Application granted granted Critical
Publication of ES2432082T3 publication Critical patent/ES2432082T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES03737378T 2002-02-07 2003-02-06 Uso de la variante de corte y empalme MGF del factor de crecimiento I similar a la insulina para la prevención del daño miocárdico Expired - Lifetime ES2432082T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0202906.4A GB0202906D0 (en) 2002-02-07 2002-02-07 Prevention of myocardial damage
GB0202906 2002-02-07
PCT/GB2003/000537 WO2003066082A1 (en) 2002-02-07 2003-02-06 Use of the insulin-like-growth factor i splice variant mgf for the prevention of myocardial damage

Publications (1)

Publication Number Publication Date
ES2432082T3 true ES2432082T3 (es) 2013-11-29

Family

ID=9930632

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03737378T Expired - Lifetime ES2432082T3 (es) 2002-02-07 2003-02-06 Uso de la variante de corte y empalme MGF del factor de crecimiento I similar a la insulina para la prevención del daño miocárdico

Country Status (9)

Country Link
US (4) US20050048028A1 (https=)
EP (1) EP1480669B1 (https=)
JP (1) JP2005516997A (https=)
AU (1) AU2003244511A1 (https=)
DK (1) DK1480669T3 (https=)
ES (1) ES2432082T3 (https=)
GB (1) GB0202906D0 (https=)
PT (1) PT1480669E (https=)
WO (1) WO2003066082A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202906D0 (en) 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
AU2006224334A1 (en) * 2005-03-18 2006-09-21 The Board Of Trustees Of The University Of Illinois Mecano growth factor peptides and their use
WO2006097682A1 (en) * 2005-03-18 2006-09-21 Ucl Business Plc Mechano growth factor peptides and their use
KR101459789B1 (ko) 2006-06-09 2014-11-07 노파르티스 아게 안정화된 인슐린-유사 성장 인자 폴리펩티드
WO2009012443A1 (en) * 2007-07-18 2009-01-22 The Board Of Trustees Of The University Of Illinois Nanoparticles for the elution of growth factors for recovery and regeneration of organs
CN101891812B (zh) * 2010-07-09 2012-10-17 山西大学 力生长因子多肽及其制备方法和用途
CN103031277B (zh) * 2011-09-29 2015-07-15 重庆大学 力生长因子在制备无血清培养耐受型哺乳动物工程细胞中的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460147C2 (de) 1974-12-19 1983-05-05 Ibm Deutschland Gmbh, 7000 Stuttgart Anordnung zur Dekomprimierung komprimierter Information für aus schwarzen und weißen Bereichen zusammengesetze darzustellende Zeichen
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US4963665A (en) 1986-01-07 1990-10-16 Washington University Human preproinsulin-like growth factor I
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
SE8703625D0 (sv) 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
DK0437563T3 (da) 1989-08-07 1995-05-29 Debio Rech Pharma Sa Bioligiske aktive lægemiddelpolymerderivater
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
SE9100099D0 (sv) 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
SE9101341D0 (sv) 1991-05-03 1991-05-03 Kabi Pharmacia Ab New medicinal use
US5861373A (en) * 1991-08-01 1999-01-19 Genentech, Inc IGF-1 to improve the neural condition
EP0597033B1 (en) 1991-08-01 1997-04-09 Genentech, Inc. Igf-1 to improve the neural condition
US5298422A (en) 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
EP0615452A4 (en) 1991-11-25 1995-07-12 Inst Molecular Biology Inc MEDICINE SERVING THE PROMOTION OF THE GROWTH OF A NERVE IN MAMMALS.
FR2687681B1 (fr) * 1992-02-20 1995-10-13 Transgene Sa Conjugues polyethyleneglycol-hirudine, leur procede de preparation et leur emploi pour le traitement des thromboses.
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
AU1178395A (en) 1993-11-12 1995-05-29 North Shore University Hospital Research Corporation Method of treating muscular dystrophy
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5650496A (en) * 1995-04-14 1997-07-22 Cephalon, Inc. IGF-I purification process
GB9605124D0 (en) * 1996-03-11 1996-05-08 Royal Free Hosp School Med Method of treating muscular disorders
US6214966B1 (en) * 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
DE69939036D1 (de) 1998-04-28 2008-08-14 Serono Lab PEG Konjugate von LHRH Analogen
GB9926968D0 (en) 1999-11-15 2000-01-12 Univ London Treatment of neurological disorders
GB0011278D0 (en) * 2000-05-10 2000-06-28 Univ London Repair of nerve damage
GB0202906D0 (en) 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
GB0203552D0 (en) 2002-02-14 2002-04-03 Beaumont Nicholas J Peptide growth factor
WO2006097682A1 (en) 2005-03-18 2006-09-21 Ucl Business Plc Mechano growth factor peptides and their use

Also Published As

Publication number Publication date
DK1480669T3 (da) 2013-05-06
WO2003066082A1 (en) 2003-08-14
US20080039390A1 (en) 2008-02-14
US20130210723A1 (en) 2013-08-15
US20050048028A1 (en) 2005-03-03
JP2005516997A (ja) 2005-06-09
GB0202906D0 (en) 2002-03-27
PT1480669E (pt) 2013-05-22
US9919031B2 (en) 2018-03-20
US20180271942A1 (en) 2018-09-27
EP1480669A1 (en) 2004-12-01
EP1480669B1 (en) 2013-01-23
AU2003244511A1 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
AU2013287281B2 (en) AAV-mediated gene therapy for RPGR x-linked retinal degeneration
US20180271942A1 (en) Use of the Insulin-Like-Growth Factor 1 Splice Variant MGF for the Prevention of Myocardial Damage
JP6046493B2 (ja) プロミニン−１の血管新生促進フラグメントおよびその使用
KR20220107243A (ko) Apoe 유전자 요법
CN116685329A (zh) 核酸构建体及其用于治疗脊髓性肌肉萎缩症的用途
US20060058239A1 (en) Use of the insulin-like-growth factor I isoform MGF for the treatment of neurological disorders
ES2936383T3 (es) Terapias basadas en transcriptasa inversa de la telomerasa para el tratamiento de afecciones asociadas con el infarto de miocardio
ES2864731T3 (es) Terapias a base de la telomerasa transcriptasa inversa
JP7575273B2 (ja) デュシェンヌ型筋ジストロフィーを治療するための組成物及び方法
KR102236843B1 (ko) 새로운 재생 치료제로서의 camkk1
EP1967210A1 (en) Novel application of apelin
US8865669B2 (en) DNA fragment and use thereof
WO1999010013A1 (en) The use of insulin-like growth factor-i in muscle
US6723707B1 (en) Use of insulin-like growth factor-I in muscle
WO2015153357A1 (en) Compositions and methods for improving cardiac function
CN115666624A (zh) 作为抗癌治疗的emid2蛋白
WO2025240625A1 (en) Cbin1 therapy improves atrial electrical and functional remodeling, limiting atrial arrhythmias in failing hearts
JP2002051786A (ja) 骨・軟骨形成組織特異的なプロモーター及びその利用
CN103127492A (zh) 一种抗丙型肝炎病毒的蛋白及其用途
Vujic Functional substitutions of amino acids that differ between GDF11 and GDF8 impact skeletal development and skeletal muscle
Harper et al. MUSCLE AND CONNECTIVE TISSUE
HK40049102A (en) Compositions and methods for treating duchenne muscular dystrophy
JP2016131541A (ja) トランスジェニック非ヒト哺乳動物及びその用途
JP2013531990A (ja) アテローム性動脈硬化症治療のための組成物および方法